# biopharma (audio feeds) — RSS Amplifier Recent posts from the 5 feeds in the RSS Amplifier directory that cover biopharma. Page: Feed: --- ## Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment _2026-08-21 · Citeline Podcasts_ One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that. [Listen](https://traffic.megaphone.fm/RSUSA4407322488.mp3) ## Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA _2026-08-18 · BioCentury This Week_ A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the financings, which included money for a potential challenger to Amgen’s blockbuster Tepezza and a new venture from immunology professor Georg Schett with backing from Deerfield Management, Boulevard Bio. The analysts… [Listen](https://www.buzzsprout.com/1035190/episodes/19662536-ep-382-summer-s-venture-wave-drugging-beta-catenin-capricor-fda.mp3) ## Strategic Intent: The Rise Of Mid-Cap Dealmakers _2026-08-17 · Citeline Podcasts_ Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs. [Listen](https://traffic.megaphone.fm/RSUSA4297745523.mp3) ## Building The GLP-1 Companion Category, With Beverley Law And Martina Gripp _2026-08-17 · Citeline Podcasts_ Everyone in consumer health is talking about GLP-1s. While this new generation of weight loss drugs is firmly on the prescription-only side, industry is now thinking about how it can meet users’ needs for products that address side effects and the nutritional gaps that come with rapid weight loss. In this episode of HBW Insight’s Over the Counter, ALL Creative founder Beverley Law and consultant… [Listen](https://traffic.megaphone.fm/RSUSA3644299698.mp3) ## Drug Fix: Understanding The PDUFA VIII Revenue Cut And GDUFA IV Name Change _2026-08-14 · Citeline Podcasts_ Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the important provisions of the new prescription drug and generic drug user fee commitment letters (:53), including the revenue cut coming in PDUFA VIII (7:16), as well as the new formal meeting names (13:53) and “America First” incentives (23:47) in GDUFA IV. More On These Topics From… [Listen](https://traffic.megaphone.fm/RSUSA2576494710.mp3) ## The State of Play in Biotech and the Decisions Shaping the Industry _2026-08-12 · Citeline Podcasts_ Biotech leaders are navigating disciplined growth, shifting global dynamics, and rising expectations across boards, partners, and clinical teams. In this opening episode, a panel of experienced biotech executives step back to discuss where the industry truly stands, the forces shaping decision‑making, and how leaders are approaching strategy, execution, and collaboration in today’s biotech… [Listen](https://traffic.megaphone.fm/RSUSA9432843516.mp3) ## Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies _2026-08-11 · Citeline Podcasts_ On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute rare disease treated in hospitals versus a large chronic ophthalmology market served by retina… [Listen](https://traffic.megaphone.fm/RSUSA1923246242.mp3) ## Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs _2026-08-11 · BioCentury This Week_ Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how stakeholders in the U.S. are responding to the challenge. The analysts also discuss the next frontiers of federated learning in drug… [Listen](https://www.buzzsprout.com/1035190/episodes/19628320-ep-381-fih-urgency-in-the-u-s-plus-federated-learning-biotech-ipos.mp3) ## Drug Fix: Regulatory Nationalism And US FDA’s IND Reforms _2026-08-07 · Citeline Podcasts_ Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the impact of nationalism on the regulatory process, which entered the fray once again when news of a potential AstraZeneca-Bristol Myers Squibb merger broke (:58), as well as the US Food and Drug Administration’s IND reform pilot program (11:22), including the potentially influential… [Listen](https://traffic.megaphone.fm/RSUSA1730059314.mp3) ## Proof of Concept - AI in Drug Discovery _2026-08-06 · Citeline Podcasts_ In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both sides — as the big-pharma adopter deciding whether to trust these tools, and as the builder creating them.… [Listen](https://traffic.megaphone.fm/RSUSA5506183401.mp3) ## [Trade Bitcoin and Ethereum Today (Sponsored)](https://crawlproof.com/a/XJvahSbDgPc5) _2026-08-06 · **Sponsored**_ Buy, sell, and margin trade BTC and ETH with EUR, USD, CAD, GBP, or JPY. ## Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS Deal _2026-08-06 · Citeline Podcasts_ Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification. [Listen](https://traffic.megaphone.fm/RSUSA2440905390.mp3) ## Podcast: China's Evolving Role in Global Clinical Development _2026-08-04 · Citeline Podcasts_ How shifting perceptions and new opportunities are changing the way sponsors approach China [Listen](https://traffic.megaphone.fm/RSUSA5386506252.mp3) ## Off-Patent, On Record: View Through The Journalist's Lens With Generics Bulletin's Dave Wallace _2026-08-04 · Citeline Podcasts_ Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor for 16 years. [Listen](https://traffic.megaphone.fm/RSUSA6211621843.mp3) ## Ep. 380 - AZ-BMS rumors, Replimune, psychedelics _2026-08-04 · BioCentury This Week_ Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it . The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in… [Listen](https://www.buzzsprout.com/1035190/episodes/19595205-ep-380-az-bms-rumors-replimune-psychedelics.mp3) ## [A Major Update to the Future of BPS](https://www.bigpharmasharma.com/p/a-major-update-to-the-future-of-bps) _2026-08-02 · Big Pharma Sharma · Big Pharma Sharma_ I’m not sure what the best way is to say this, so I’ll just be direct. ## [Last Week Tonight in BioPharma: Week of July 27th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-a92) _2026-08-01 · Big Pharma Sharma · Big Pharma Sharma_ Novo's IL-6 fails to curb CV events, new life for Replimune, and ArgenX makes an acquisition ## [Lance Baldo: CEO of Beacon Therapeutics](https://wyantsimboli.com/bioboss/lance-baldo-ceo-of-beacon-therapeutics) _2026-07-29 · BioBoss_ Lance Baldo, CEO of Beacon Therapeutics, shares his insights about leadership in biopharma and how Beacon is working to save and restore sight for people living with rare and prevalent ocular diseases. [Listen](https://www.buzzsprout.com/236855/episodes/19570102-lance-baldo-ceo-of-beacon-therapeutics.mp3) ## Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard _2026-07-28 · BioCentury This Week_ Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can run the strategy that has made autoimmune drug Vyvgart efgartigimod alfa a blockbuster. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the deal and put it in the context of a new cohort of large-cap… [Listen](https://www.buzzsprout.com/1035190/episodes/19559704-ep-379-argenx-m-a-ai-giants-and-biopharma-catalyst-scorecard.mp3) ## [Summer Rhythm: Getting Ready for Fall](https://suenemetz.libsyn.com/summer-rhythm-getting-ready-for-fall) _2026-07-27 · Connecting the Dots_ Use this time intentionally. [Listen](https://traffic.libsyn.com/secure/suenemetz/e48_Summer_Rhythm.mp3?dest-id=1917308) ## [Last Week Tonight in BioPharma: Week of July 20, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-dda) _2026-07-26 · Big Pharma Sharma · Big Pharma Sharma_ GSK becomes a commercial player in lung cancer, retatrutide raises concerns about cardiovascular risk, and Novo sues Lilly over its GLP-1 ads. ## [Watch chovy live code (Sponsored)](https://crawlproof.com/a/L2tCcEoK5woy) _2026-07-26 · **Sponsored**_ Join Mosh Coding streams with collaborative screen sharing and remote control, open source. ## Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data _2026-07-21 · BioCentury This Week_ The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what Vallance’s exit, the appointment of John Healey as Chancellor of the Exchequer and other changes arriving with the new Prime Minister could mean for life sciences in the country. BioCentury’s analysts also discuss an ambitious U.K. data… [Listen](https://www.buzzsprout.com/1035190/episodes/19523181-ep-378-u-k-cabinet-shuffle-taiwan-biotech-and-biogen-data.mp3) ## [Last Week Tonight in BioPharma: Week of July 13th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-58d) _2026-07-19 · Big Pharma Sharma · Big Pharma Sharma_ Oral PCSK9 inhibitor approval, Kalshi wants to predict trial outcomes, Lilly acquires Atai Beckley, and more! ## Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson _2026-07-15 · BioCentury This Week_ After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector’s traditional hubs. On a special episode of the BioCentury This Week podcast, Ian Anderson, senior director, head of U.S. life sciences & healthcare research at CBRE, joins BioCentury’s analysts to discuss the company’s recent report… [Listen](https://www.buzzsprout.com/1035190/episodes/19500038-ep-377-trends-in-life-sciences-talent-with-cbre-s-ian-anderson.mp3) ## [Will That Be Cash or Credit?](https://www.bigpharmasharma.com/p/will-that-be-cash-or-credit) _2026-07-15 · Big Pharma Sharma · Big Pharma Sharma_ Pay attention to the way Big Biopharma pays for its acquisitions — it can tell you a lot ## Ep. 376 - M&A momentum: 3Q public markets preview _2026-07-14 · BioCentury This Week_ M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview , asking whether M&A momentum can carry biotech through year-end and what happens if the AI trade goes bust? Editor in Chief Simone Fishburn gives her perspective on what incoming Prime Minister Andy Burnham’s… [Listen](https://www.buzzsprout.com/1035190/episodes/19490358-ep-376-m-a-momentum-3q-public-markets-preview.mp3) ## [Last Week Tonight in BioPharma: Week of July 7th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-380) _2026-07-13 · Big Pharma Sharma · Big Pharma Sharma_ Vertex swings big for Crinetics, Ionis' results boost BridgeBio, and a Vera introduces TRUTAKNA to the IgAN market ## Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech _2026-07-07 · BioCentury This Week_ Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how the deal fits with the Swiss pharma’s cancer toolkit. The analysts then discuss MHRA CEO Lawrence Tallon’s Guest Commentary in BioCentury on making regulation a catalyst for U.K.… [Listen](https://www.buzzsprout.com/1035190/episodes/19455271-ep-375-novartis-adc-gambit-regulation-as-catalyst-for-u-k-biotech.mp3) ## [Last Week Tonight in BioPharma: Week of June 29th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-41b) _2026-07-05 · Big Pharma Sharma · Big Pharma Sharma_ Anthropic wants to make drugs, a new "diva" in KRAS, Ipsen goes shopping, BridgeBio gets a "billy", and more! ## Ep. 374 - Parkinson's deep dive & FDA trial reforms _2026-06-29 · BioCentury This Week_ New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts review the most promising targets and trends shaping the Parkinson’s treatment landscape. The team then turns to AstraZeneca’s build-out of its obesity portfolio, followed by FDA’s… [Listen](https://www.buzzsprout.com/1035190/episodes/19420756-ep-374-parkinson-s-deep-dive-fda-trial-reforms.mp3) ## [Last Week Tonight in BioPharma: Week of June 22nd, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-885) _2026-06-28 · Big Pharma Sharma · Big Pharma Sharma_ Seagen ADC 2L NSCLC failure, Trump might be on retatrutide, US-China deal drama, and much more. ## [Earn crypto for idle GPUs (Sponsored)](https://crawlproof.com/a/jWBeFCalR5oD) _2026-06-28 · **Sponsored**_ Run one CLI, host Qwen/Llama/Mistral, and earn BTC, ETH, SOL, or USDC ## [Shaun Bagai: CEO of RenovoRX](https://wyantsimboli.com/bioboss/shaun-bagai-ceo-of-renovorx) _2026-06-25 · BioBoss_ Shaun Bagai, CEO of RenovoRX, shares his insights about leadership in biopharma and how RenovoRX is working to develop targeted oncology therapies and commercialize its FDA cleared drug delivery device. [Listen](https://www.buzzsprout.com/236855/episodes/19396869-shaun-bagai-ceo-of-renovorx.mp3) ## Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first _2026-06-23 · BioCentury This Week_ AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeout and the assets AbbVie gains. The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency’s former leadership and assess Acting CDER… [Listen](https://www.buzzsprout.com/1035190/episodes/19387537-ep-373-abbvie-m-a-fda-reversals-a-car-t-first.mp3) ## [The Identity Crisis at the Heart of Medical Affairs](https://suenemetz.libsyn.com/the-identity-crisis-at-the-heart-of-medical-affairs) _2026-06-22 · Connecting the Dots_ How Medical Affairs is regaining its power. [Listen](https://traffic.libsyn.com/secure/suenemetz/e47_Medical_Affairs_Crisis.mp3?dest-id=1917308) ## [Last Week Tonight in BioPharma, Week of June 15, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-655) _2026-06-22 · Big Pharma Sharma · Big Pharma Sharma_ Abbvie + Apogee, Neumora strikes out, Jazz bets on Abcellera, and the FDA starts to turn the page from the Prasad-Makary era. ## [Cell Therapy is Making Progress Against Solid Tumors — But is Anyone Noticing?](https://www.bigpharmasharma.com/p/cell-therapy-is-making-progress-against) _2026-06-18 · Big Pharma Sharma · Big Pharma Sharma_ Three under-the-radar cell therapy readouts from ASCO 2026 and where the near-term commercial future for this class may lie ## [Last Week Tonight in BioPharma: Week of June 8th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-84b) _2026-06-15 · Big Pharma Sharma · Big Pharma Sharma_ A major GSK acquisition, Tango puts PRMT5 back on the radar, a record-setting IPO, and much more! ## [ASCO 2026: Attention might be on the Wrong Drug in Frontline Lung Cancer](https://www.bigpharmasharma.com/p/asco-2026-attention-might-be-on-the) _2026-06-09 · Big Pharma Sharma · Big Pharma Sharma_ Sac-TMT may be unlike other TROP2 ADCs and poses a real threat to the PD-1xVEGF class in 1L NSCLC ## [Last Week Tonight in BioPharma: Week of June 1st, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-0c6) _2026-06-06 · Big Pharma Sharma · Big Pharma Sharma_ RevMed PDAC data, IgAN opportunity, CAR-T for kidney transplant, NewLimit Series C, and much more ## [Last Week Tonight in BioPharma: Week of May 25th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-c73) _2026-05-31 · Big Pharma Sharma · Big Pharma Sharma_ Lilly' PCSK9 gene editing data, HBV functional cure, GLP-1 formulary update, Pfizer looks to China to reinvigorate its pipeline, and more! ## [ChatGPT, Claude, or Gemini? Big Pharma Is Choosing Sides](https://www.bigpharmasharma.com/p/chatgpt-claude-or-gemini-big-pharma) _2026-05-27 · Big Pharma Sharma · Big Pharma Sharma_ I tracked 27 frontier-AI partnerships across 21 pharma companies. Here’s what the map looks like and what it means. ## [Last Week Tonight in BioPharma: Week of May 18, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-d6d) _2026-05-24 · Big Pharma Sharma · Big Pharma Sharma_ Retatrutide wows, Sac-TMT continues to shine, Regeneron co-signs Parabilis, and much more! ## [Last Week Tonight in BioPharma: Week of May 11th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-1ee) _2026-05-17 · Big Pharma Sharma · Big Pharma Sharma_ Novo's early responders play, cleaning house at the FDA, IsoMorphic's $2.1B round, and more! ## [We Know JAK About Myelofibrosis](https://www.bigpharmasharma.com/p/we-know-jak-about-myelofibrosis) _2026-05-15 · Big Pharma Sharma · Big Pharma Sharma_ Myelofibrosis treatment hasn't changed much for a long time. Is there a breakthrough on the horizon? ## [The Human Role in Launch Readiness](https://suenemetz.libsyn.com/the-human-role-in-launch-readiness) _2026-05-15 · Connecting the Dots_ Your Launch Plan Is Ready. Your People Aren't. [Listen](https://traffic.libsyn.com/secure/suenemetz/05_May_26_Launch_Planning_v2.mp3?dest-id=1917308) ## [Last Week Tonight in BioPharma: Week of May 4th](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-576) _2026-05-10 · Big Pharma Sharma · Big Pharma Sharma_ Happy Mother's Day! This week: Cytokinetics, Makary (almost) out, Roche buys PathAI, and more! ## [Hyung Heon Kim: CEO of MetaVia](https://wyantsimboli.com/bioboss/hyung-heon-kim-ceo-of-metavia) _2026-05-06 · BioBoss_ Hyung Heon Kim, CEO of MetaVia, shares his insights about leadership in biopharma and how MetaVia is working to transform cardiometabolic disease. [Listen](https://www.buzzsprout.com/236855/episodes/19128116-hyung-heon-kim-ceo-of-metavia.mp3) ## [Last Week Tonight in Biopharma: Week of April 27th, 2026](https://www.bigpharmasharma.com/p/last-week-tonight-in-biopharma-week-0fc) _2026-05-03 · Big Pharma Sharma · Big Pharma Sharma_ Sun Pharma buying Organon, AstraZeneca's dance with the ODAC, Intellia pays the "gene therapy tax", and IPOs are back! ## [Process Unleashes Innovation](https://suenemetz.libsyn.com/process-unleashes-innovation) _2026-04-21 · Connecting the Dots_ With effective strategic planning in life sciences. [Listen](https://traffic.libsyn.com/secure/suenemetz/e46_Process_Unleashes_Innovation.mp3?dest-id=1917308) ## [David Southwell: CEO of Volastra Therapeutics](https://wyantsimboli.com/bioboss/david-southwell-ceo-of-volastra-therapeutics) _2026-02-28 · BioBoss_ David Southwell, CEO of Volastra Therapeutics, shares his insights about leadership in biopharma and how Volastra is working to discover and develop oncology therapeutics targeting chromosomal instability, a vulnerability of cancers. [Listen](https://www.buzzsprout.com/236855/episodes/18761536-david-southwell-ceo-of-volastra-therapeutics.mp3) ## [Medical Affairs Today – A discussion with two experts](https://suenemetz.libsyn.com/medical-affairs-today-a-discussion-with-two-experts) _2026-02-23 · Connecting the Dots_ [Listen](https://traffic.libsyn.com/secure/suenemetz/e45_Medical_Affairs_Today.mp3?dest-id=1917308)